Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,420.47
(
0.16%
)
US TECH 100
28,355.60
(
-0.01%
)
Dow Jones
49,672.45
(
0.30%
)
Brent Oil
106.64
(
-0.78%
)
Bitcoin
76,405.93
(
-1.29%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 206704

Wednesday, 12/07/2016 9:41:26 AM

Wednesday, December 07, 2016 9:41:26 AM

Post# of 257580
RVNC—Just to be clear, SAKURA is the name for the entire phase-3 program of RT002 in glabellar lines, which consists of: two identical randomized, controlled efficacy trials, where patients receive a single treatment; and one open-label safety trial where some patients receive a second treatment and are followed for as long as 84 weeks.

Someone on Twitter asked if there will be an interim analysis in the efficacy trials; the answer is no—it wouldn't make any sense in this kind of trial.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today